Kynurenic acid: A new effector of valproate action?

Pharmacological Reports

Volumn 63, Issue 6, 2011, Pages 1569-1573

  Maciejak, Piotr ^a,b   Szyndler, Janusz ^b   Turzyńska, Danuta ^a   Sobolewska, Alicja ^a   Płaźnik, Adam ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Epilepsy; GABA; Kynurenic acid; Microdialysis; Neuroprotection; PTZ kindling; Steady state; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; KYNURENIC ACID; VALPROIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CELL ACTIVITY; CONTROLLED STUDY; HIPPOCAMPUS; MALE; NERVE CELL; NONHUMAN; PROTEIN FUNCTION; RAT;

EID: 84857491748     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70723-X     Document Type: Article

References (20)

1. Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W: Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther, 2007, 320, 331-343. (Pubitemid 46025748)
2. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B et al.: Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry, 2006, 11, 1116-1125. (Pubitemid 44867481)
3. Czuczwar M, Cieszczyk J, Czuczwar K, Kioe J, Saran T, Turski WA: Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice. Pharmacol Rep, 2009, 61, 732-736.
4. Foster AC, Vezzani A, French ED, Schwarcz R: Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett, 1984, 48, 273-278. (Pubitemid 14054435)
5. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR: Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J Neurochem, 1991, 56, 2007-2017.
6. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci, 2001, 21, 7463-7473. (Pubitemid 32904945)
7. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM: Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther, 2007, 321, 892-901. (Pubitemid 46762687)
8. Kocki T, Wielosz M, Turski WA, Urbanska EM: Enhancement of brain kynurenic acid production by anticonvulsants - Novel mechanism of antiepileptic activity? Eur J Pharmacol, 2006, 541, 147-151. (Pubitemid 43903484)
9. Konradsson-Geuken B, Wu HQ, Gash CR, Alexander KS, Campbell A, Sozeri Y, Pellicciari R et al.: Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience, 2010, 169, 1848-1859.
10. Leng Y, Chuang DM: Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci, 2006, 26, 7502-7512. (Pubitemid 44315219)
11. Maciejak P, Szyndler J, Turzyńska D, Sobolewska A, Taracha E, Skórzewska A, Lehner M et al.: Time course of changes in the concentration of kynurenic acid in the brain of pentylenetetrazol-kindled rats. Brain Res Bull, 2009, 78, 299-305.
12. Mann EO, Paulsen O: Role of GABAergic inhibition in hippocampal network oscillations. Trends Neurosci, 2007, 30, 343-349. (Pubitemid 46991119)
13. Miranda AF, Boegman RJ, Beninger RJ, Jhamandas K: Protection against quinolinic-acid mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience, 1997, 78, 967-975. (Pubitemid 27223703)
14. Racine RJ, Gartner JG, Burnham WM: Epileptiform activity and neural plasticity in limbic structures. Brain Res, 1972, 47, 262-268.
15. Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci, 2007, 64, 2090-2103.
16. Scharfman HE, Goodman JH, Schwarcz R: Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids, 2000, 19, 283-297.
17. Szyndler J, Maciejak P, Turzyńska D, Sobolewska A, Lehner M, Taracha E, Walkowiak J et al.: Changes in the concentration of amino acids in the hippocampus of pentylenetetrazole-kindled rats. Neurosci Lett, 2008, 439, 245-249.
18. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L: The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci, 2009, 283, 21-27.
19. Wejksza K, Rzeski W, Turski WA: Kynurenic acid protects against the homocysteine-induced impairment of endothelial cells. Pharmacol Rep, 2009, 61, 751-756.
20. Wojtal K, Borowicz KK, Błaszczyk B, Czuczwar SJ: Interactions of excitatory amino acid receptor antagonists with antiepileptic drugs in three basic models of experimental epilepsy. Pharmacol Rep, 2006, 58, 587-598. (Pubitemid 44741678)